14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Humanß3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.

Asahi Kasei Pharma
Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP(1) receptor antagonists for treatment of overactive bladder by core structure replacement.

Asahi Kasei Pharma
Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping.

Asahi Kasei Pharma
SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.

Asahi Kasei Pharma
A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.

Asahi Kasei Pharma
Design of cyclic peptides with agonist activity at melanocortin receptor-4.

Asahi Kasei Pharma
Discovery of selective PDE4B inhibitors.

Asahi Kasei Pharma
Discovery of 4,6- and 5,7-Disubstituted Isoquinoline Derivatives as a Novel Class of Protein Kinase C ζ Inhibitors with Fragment-Merging Strategy.

Asahi Kasei Pharma
The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain.

Asahi Kasei Pharma
Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.

Asahi Kasei Pharma
Discovery of a novel 2-(1H-pyrazolo[3,4-b]pyridin-1-yl)thiazole derivative as an EP

Asahi Kasei Pharma
Discovery of Novel Indazole Derivatives as Orally Availableβ

Asahi Kasei Pharma
COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS

Beth Israel Deaconess Medical Center
IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS

Deutsches Krebsforschungszentrum